Herbalife (HLF) Q3 2026 Earnings Call Transcript

Herbalife reported Q3 net sales of $1.4 billion, up 6% year over year (7.6% in constant currency), and adjusted EBITDA of $182.4 million, above its $160 million–$180 million guidance range; adjusted EBITDA margin expanded 70bps to 13.5%. The company raised full-year reported net sales growth guidance to 4.9%–5.9%, maintained reported adjusted EBITDA guidance at $670 million–$690 million, and authorized a $250 million share repurchase program over three years. Net leverage reached its target of 2.0x, while management cautioned that Q4 margin would be lower than Q3 and further expansion would be more gradual.

Analysis

The beat is less broad-based than headline growth suggests: India’s reported dollar contribution exceeded the company’s total net-sales increase, implying meaningful offsets elsewhere. That makes the next few quarters a test of whether growth can broaden as the favorable India comparison fades—not simply whether India remains strong. North America’s improvement also includes a prior-period revenue-timing benefit, so it is not yet clean evidence of a durable regional inflection.

Margin quality is the near-term constraint. Pricing and lower interest expense support earnings, but mix and manufacturing/input costs pressure gross margin; fourth-quarter EBITDA guidance implies a sequential margin step-down, while full-year reported EBITDA guidance was not raised with sales. The refinancing and leverage progress reduce balance-sheet risk, but the three-year buyback authorization is not an immediate earnings catalyst and competes with investment needs if growth initiatives require more spending.

Over 1–3 months, watch Q4 margin delivery, India growth excluding the GST comparison effect, and whether non-India regions contribute. Over 6–18 months, the modular distributor platform and Bioniq could improve retention, customer insight and access to new buyers, but management’s transaction-capture ambition is not evidence of adoption or monetization. GLP-1 is a two-sided, unproven opportunity: protein positioning may complement treatment, while weight-management demand and consumer behavior could change. A reversal case is renewed input-cost pressure, weaker India momentum, or technology rollout that adds cost without improving distributor productivity. Valuation and the post-call share reaction are unavailable, limiting conviction on a price-sensitive entry.

Key Decisions for Investors

• Do not chase the earnings beat. Keep HLF neutral pending the market reaction and Q4 guidance revisions; the result supports operating stabilization, not yet a broad-based growth re-rating.
• Watch for a pullback with reported EBITDA guidance intact as a possible entry window for a small, staged long. Reassess or exit the thesis if management cuts EBITDA guidance, gross-margin pressure accelerates, or India weakens without offsetting regional growth.
• Treat the 2027 digital rollout and Bioniq expansion as catalysts to monitor, not current valuation support. Look for disclosed adoption, repeat purchasing, and measurable distributor productivity before underwriting material incremental earnings.